Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, prompting a negative market reaction. Management cited continued pricing pressure, especially in its branded diabetes product BAQSIMI, and increased competition in selected product categories as key drivers behind the results. CFO William Peters acknowledged, “The pricing issue that we've been encountering appears to be potentially the increase of -- there's multiple things going on there. One, there's some increased rebates, but also potentially, we believe some duplicate rebates, which seems to be a 340B pharmacy issue.”

Is now the time to buy AMPH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call

• Serge Belanger (Needham & Company) asked about the duration and nature of BAQSIMI pricing pressures and the impact of exiting certain international markets. CFO William Peters explained that pricing issues stem from increased and potentially duplicate rebates, and that international exits will be gradual, with limited top-line impact.
• Anthea Li (Jefferies) inquired about timelines and regulatory status for the synthetic corticotropin and insulin aspart biosimilar programs. EVP Tony Marrs confirmed that regulatory meetings have not yet occurred for corticotropin and reaffirmed a 2027 launch target for insulin aspart.
• Ekaterina Knyazkova (JPMorgan) questioned the commercial potential and ramp for the insulin aspart biosimilar as well as future trends in glucagon sales. Peters indicated that the product represents a significant market opportunity but will require time to ramp depending on interchangeability status, while glucagon sales are expected to decline further but at a slower rate.
• Naoki Martin (Piper Sandler) asked about potential generic competition for Primatene MIST and revenue expectations for the newly launched ipratropium bromide product. EVP Dan Dischner stated there is no visibility on imminent generics for Primatene MIST and that ipratropium bromide is expected to be a key growth driver in the near term.
• No further analyst questions were addressed on the call.

Catalysts in Upcoming Quarters

Looking ahead, our team will be watching (1) the effectiveness of Amphastar’s pricing and rebate management actions for BAQSIMI, (2) the sales trajectory of the newly launched generic ipratropium bromide inhalation product, and (3) regulatory and development progress toward late-stage pipeline launches targeted for 2027. Updates on cost management and competitive responses in core categories will also be important indicators of execution.

Amphastar Pharmaceuticals currently trades at $18.32, down from $24.03 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.